1. Introduction {#sec1}
===============

Increased life spans in the Western world have led to an elevated frequency of neurodegenerative diseases, such as Alzheimer\'s disease and Parkinson\'s disease. Neurodegenerative diseases are the result of gradual and progressive loss of neural cell function.

Oxidative damage plays a pivotal role in the initiation and progress of many human diseases and is considered to be a salient and early pathogenetic event in many neurodegenerative disorders that are characterized by selective neuronal death \[[@B1]--[@B5]\]. Compared with other tissues, the brain is particularly vulnerable to oxidative damage due to its high rate of oxygen utilization and the great deal of oxidizable polyunsaturated fatty acids it contains \[[@B6], [@B7]\]. In addition, certain regions of the brain are rich in iron, a metal that is catalytically involved in the production of damaging reactive oxygen species (ROS) \[[@B8]\]. Although ROS are critical intracellular signaling messengers \[[@B9]\], an excess of free radicals may lead to peroxidative impairment of membrane lipids and, consequently, to the disruption of neuronal functions and apoptosis. The ROS known to be responsible for neurotoxicity are hydrogen peroxide (H~2~O~2~), superoxide anions (O~2~^−^), and hydroxyl radicals (OH^−^).

Brain cells have the capacity to produce large quantities of peroxides, particularly H~2~O~2~ \[[@B10]\]. Excess, H~2~O~2~ accumulates in response to brain injuries and during the course of neurodegenerative diseases and can cross cell membranes to elicit biological effects from inside the cells \[[@B11]\]. Although H~2~O~2~ is generally not very reactive, it is thought to be the major precursor of highly reactive free radicals that may cause damage in the cell, through iron ion- or copper ion-mediated oxidation of lipids, proteins, and nucleic acids. This capability can partially account for H~2~O~2~-mediated neuronal \[[@B12]\] and glial \[[@B13]\] death. H~2~O~2~ also induces differential protein activation, which accounts for its varied biological effects. In the mammalian central nervous system (CNS), the transition metal zinc is found only in the synaptic vesicles of glutamatergic neurons and plays a special role in modulating synaptic transmission. Chelatable zinc is released into the synaptic cleft with the neurotransmitter during neuronal execution \[[@B14]\]. Under normal circumstances, the robust release of zinc is transient and the zinc is efficiently cleared from the synaptic cleft to ensure the performance of successive stimuli. However, under pathological conditions, elevated levels of extracellular zinc have been recognized as an important factor in neuropathology \[[@B15]--[@B17]\]. In neurotransmission, the amount of zinc in the synaptic cleft is in the range of 10 to 30 *μ*M, but, under pathological conditions that involve sustained neuronal depolarization (e.g., ischemia, stroke or traumatic brain injury), the concentration of extracellular zinc can increase to 100 to 400 *μ*M, which can contribute to the resulting neuropathology \[[@B18], [@B19]\]. *In vivo* and *in vitro* studies have shown that at concentrations that can be reached in the mammalian CNS during excitotoxic episodes, injuries or diseases, zinc induces oxidative stress and ROS production, which contribute to the death of both glial cells \[[@B20]\] and neurons \[[@B21], [@B22]\]. Zinc has been shown to decrease the glutathione (GSH) content of primary cultures of astrocytes \[[@B20], [@B23]\], increase their GSSG content \[[@B23]\], and inhibit glutathione reductase activity in these cells \[[@B24]\]. Furthermore, it slows the clearance of exogenous H~2~O~2~ by astrocytes and promotes intracellular production of ROS \[[@B24]\]. Thus, ROS generation, glutathione depletion, and mitochondrial dysfunction may be key factors in ZnCl~2~-induced glial toxicity \[[@B20]\].

Astrocytes are the most abundant type of glial cell in the brain and play multiple roles in the protection of brain cells. Under ischemic conditions, astrocytes can remove excess glutamate and K^+^ to protect neurons from glutamate-mediated cytotoxicity and depolarization \[[@B25], [@B26]\]. Astrocytes can also supply energy and promote neurogenesis and synaptogenesis in response to ischemia-induced brain damage \[[@B27], [@B28]\]. Astrocytes release multiple neurotrophic factors, such as GDNF, to protect themselves and neighboring cells from *in vitro* ischemia and there is evidence that dysfunctional astrocytes can enhance neuronal degeneration by decreasing the secretion of trophic factors \[[@B29]\]. GDNF can promote the survival of substantia nigra dopaminergic neurons, induce neurite outgrowth and sprouting \[[@B30]--[@B32]\], upregulate tyrosine hydroxylase expression, and enhance synaptic efficacy \[[@B33]\]. Moreover, GDNF has been shown to protect cultured astrocytes from apoptosis after ischemia by inhibiting the activation of caspase-3 \[[@B34]\].

The study of astrocytes is particularly important in light of the coexistence of apoptotic death of neurons and astrocytes in brains affected by ischemia and neurodegenerative diseases. Despite their high levels of antioxidative activity, astrocytes exhibit a high degree of vulnerability and are not resistant to the effects of ROS. They respond to substantial or sustained oxidative stress with increased intracellular Ca^2+^, loss of mitochondrial potential, and decreased oxidative phosphorylation \[[@B35]\]. Since astrocytes determine the brain\'s vulnerability to oxidative injury and form a tight functional unit with neurons, impaired astrocytic energy metabolism and antioxidant capacity and the death of astrocytes may critically impair neuronal survival \[[@B36], [@B37]\]. Thus, protection of astrocytes from oxidative stress appears essential for the maintenance of brain function.

Based on the pathophysiological roles of astrocytes in ischemic brains, it appears that astrocyte damage causes impairment of brain function during cerebral ischemia. In recent years, there has been an increased interest in plants as a source of bioactive substances that might be developed as potential nutraceuticals and various activities of such substances have been demonstrated in *in vitro* and *in vivo* experimental systems \[[@B38]\]. Several studies have shown that some herbal medications and antioxidants show promise toward preventing Alzheimer\'s disease \[[@B39]--[@B41]\].

*Pulicaria incisa* (*Pi*) is a desert plant that belongs to the *Asteraceae* family and has been used for many years in traditional medicine for the treatment of heart disease and as a hypoglycemic agent \[[@B42]--[@B44]\]. *Pi* has been found to contain high amount of unsaturated fatty acids \[[@B45]\], to decrease total lipid, total cholesterol, and triglyceride levels, and has been proposed as a potential hypocholesterolemic agent \[[@B46]\]. A *Pi* infusion is consumed in place of tea by many Egyptian Bedouins \[[@B42], [@B43], [@B47]\]. To the best of our knowledge, its effects in the context of neurodegenerative diseases have not yet been studied.

In light of the fact that oxidative stress has become accepted as a target of therapeutic interventions for the treatment of brain injuries and neurodegenerative diseases and the critical role of astrocytes in neuronal survival, the present study examined the effects of an infusion prepared from *Pi* on the susceptibility of astrocytes to oxidative stress.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Dulbecco\'s Modified Eagle\'s Medium (DMEM), Leibovitz-15 medium, glutamine, antibiotics (10,000 IU/mL penicillin and 10,000 *μ*g/mL streptomycin), soyabean trypsin inhibitor, and fetal bovine serum (FBS) were purchased from Biological Industries (Beit Haemek, Israel); dimethyl sulphoxide (DMSO) was obtained from Applichem (Darmstadt, Germany) and hydrogen peroxide (H~2~O~2~) was obtained from MP Biomedicals (OH, USA). ZnCl~2,~2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2′7′-dichlorofluorescein diacetate (DCF-DA) were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). 2,2′-Azobis(amidinopropane) (ABAP) was obtained from Wako chemicals (Richmond, VA,USA).

2.2. Experimental Animals {#sec2.2}
-------------------------

Newborn Wistar rats (0--2 days old) were obtained from Harlan Laboratories. The experiments were performed in compliance with the appropriate laws and institutional guidelines and were approved by the Institutional Animal Care and Use committee of the Volcani Center, Agricultural Research Organization (number IL-135/07).

2.3. Preparation of *Pi* Infusion {#sec2.3}
---------------------------------

The plants were collected in Nekarot Wadi in the Arava Valley on April, 2005, and the plant\'s voucher specimen (M86) has been kept and authenticated as part of the Arava Rift Valley Plant Collection; VPC (Dead Sea & Arava Science Center, Central Arava Branch, Israel, [http://www.deadseaarava-rd.co.il/\_Uploads/](http://www.deadseaarava-rd.co.il/_Uploads/dbsAttachedFiles/Arava_Rift_Valley_Plant_Collection.xls)[dbsAttachedFiles/Arava_Rift_Valley_Plant_Collection.xls](http://www.deadseaarava-rd.co.il/_Uploads/dbsAttachedFiles/Arava_Rift_Valley_Plant_Collection.xls)) under the accession code AVPC0193. Freshly collected plants were dried in 40°C for three days. Preparation of *Pi* infusion was initiated by soaking a 15 mL tube containing dried *Pi* (1 gr/10 mL) in a beaker containing 200 mL boiling DDW. The beaker was allowed to cool at RT for 30 min. The tube was centrifuged (4000 RPM, 10 min, RT), the supernatant was collected, filtered, and aliquots were stored at −20°C until use. In order to determine the extract concentration, a sample of the filtered supernatant was lyophilized to obtain extract powder. The averaged concentration of the various preparations that were tested was 10 mg/mL.

2.4. Preparation of Primary Astrocytes Cultures {#sec2.4}
-----------------------------------------------

Cultures of primary rat astrocytes were prepared from cerebral cortices of 1-to-2-day-old neonatal Wistar rats. Briefly, meninges and blood vessels were carefully removed from cerebral cortices kept in Leibovitz-15 medium; brain tissues were dissociated by trypsinization with 0.5% trypsin (10 min, 37°C, 5% CO~2~); cells were washed first with DMEM containing soybean trypsin inhibitor (100 *μ*g/mL) and 10% FBS and then with DMEM containing 10% FBS. Cells were seeded in tissue culture flasks precoated with poly-D-lysine (PDL, 20 *μ*g/mL in 0.1 M borate buffer pH 8.4) and incubated at 37°C in humidified air with 5% CO~2~. The medium was changed on the second day and every second day thereafter. At the time of primary cell confluence (day 10), microglial and progenitor cells were discarded by shaking (180 RPM, 37°C) for 24 h. Astrocytes were then replated on 24-well PDL-coated plastic plates, (a) for toxicity assays, at a concentration of 1 × 10^5^/well, in DMEM (without phenol red) containing 2% FBS, 2 mM glutamine, 100 U/mL pennicilin, and 100 *μ*g/mL streptomycin. (b) For the cellular antioxidant activity assay at a concentration of 3 × 10^5^/well, in DMEM containing 10% FBS 8 mM HEPES, 2 mM glutamine, 100 U/mL pennicilin, and 100 *μ*g/mL streptomycin.

2.5. Treatment of Astrocytes {#sec2.5}
----------------------------

Twenty four hours after plating, the original medium in which the cells were grown was aspirated off, and fresh medium was added to the cells. Dilutions of *Pi* infusion, ABAP, DCF-DA, zinc, and of H~2~O~2~ in the growth medium were made freshly from stock solutions prior to each experiment and were used immediately.

2.6. Evaluation of Intracellular ROS Production {#sec2.6}
-----------------------------------------------

Intracellular ROS production was detected using the nonfluorescent cell permeating compound, 2′,7′-dichlorofluorescein diacetate (DCF-DA). DCF-DA is hydrolyzed by intracellular esterases and then oxidized by ROS to a fluorescent compound 2′-7′-DCF. Astrocytes were plated onto 24-well plates (300,000 cells/well) and treated with DCF-DA (20 *μ*M) for 30 min at 37°C. Following incubation with DCF, cultures were rinsed twice with PBS and then resuspended. (1) For measurement of H~2~O~2~-induced ROS: in DMEM containing 10% FBS, 8 mM HEPES, 2 mM glutamine, 100 U/mL penicillin, and 100 *μ*g/mL streptomycin. (2) For measurement of ZnCl~2~-induced ROS: in a defined buffer containing 116 mM NaCl, 1.8 mM CaCl~2~, 0.8 mM MgSO~4~, 5.4 mM KCl, 1 mM NaH~2~PO~4~, 14.7 mM NaHCO~3~, and 10 mM HEPES, pH, 7.4. The fluorescence was measured in a plate reader with excitation at 485 nm and emission at 520 nm.

2.7. Cellular Antioxidant Activity of *Pi* Infusion {#sec2.7}
---------------------------------------------------

Peroxyl radicals are generated by thermolysis of 2,2′-Azobis(amidinopropane) (ABAP) at physiological temperature. ABAP decomposes at approximately 1.36 × 10^−6^ s^−1^ at 37°C, producing at most 1 × 10^12^ radicals/mL/s \[[@B48]--[@B50]\]. Astrocytes were plated onto 24 wells plates (300,000 cells/well) and were incubated for 1 hr with *Pi*infusion. Then astrocytes were preloaded with DCF-DA for 30 min, washed, and ABAP (0.6 mM final concentration) was then added. The fluorescence, which indicates ROS levels, was measured in a plate reader with excitation at 485 nm and emission at 520 nm.

2.8. Induction of GDNF in Astrocytes {#sec2.8}
------------------------------------

Astrocytes were replated at 6-well PDL-coated plastic plates at a density of 2 × 10^6^/well, in DMEM/F12 containing 5% FBS, 2 mM glutamine, 100 U/mL pennicilin, and 100 *μ*g/mL streptomycin. Twenty-four hr after plating, the original medium of the cells was aspirated off and fresh medium was added to the cells. Cells were then lysed and collected using RLT buffer containing 1%  *β*ME for RNA extraction.

2.9. Quantitative Real-Time PCR Analysis {#sec2.9}
----------------------------------------

RNA was extracted by the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. Genomic DNA was removed from the RNA samples by using 50 units of RNase-free DNaseI at 37°C for 1 h. RNA (20 *μ*g) was converted to cDNA using the Thermo Scientific Verso cDNA kit (Thermo Fisher Scientific Inc.) following the manufacturer\'s protocol. The cDNA was used for quantitative real-time PCR amplification with TaqMan chemistry (Applied Biosystems) using Rat GDNF predesigned TaqMan Gene Expression Assay from Applied Biosystems (Assay ID Rn00569510). Values were normalized relative to rat glyceraldehyde-3-phospahte dehydrogenase (GAPDH; Assay ID Rn00569510). All results from three technical replicates were normalized to GAPDH and expressed as relative expression ratios calculated (relative quantity, RQ) using the comparative method and based on the data that were created by the ABI PRISM 7700 Sequence Detection System (using version 1.6 software).

2.10. Determination of Cell Viability {#sec2.10}
-------------------------------------

Cell viability was determined using a commercial colorimetric assay (Roche Applied Science, Germany) according to the manufacturer\'s instructions. This assay is based on the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the growth medium.

2.11. Determination of the Free Radical Scavenging Activity in the DPPH Assay {#sec2.11}
-----------------------------------------------------------------------------

Antioxidant activity was measured using the 2,2-diphenyl-1-picryhydrazyl DPPH radical scavenging assay. Different dilutions of the infusion (0.15 mL) were added to 1 mL of DPPH (3.9 mg/100 mL methanol) in test tubes wrapped in aluminum foil. Absorbance (A) was measured at 517 nm after 15 min incubation in the dark. All measurements were made with distilled water as blank. The scavenging ability (%) of the samples was calculated as (A~control~ − A~sample~)/A~control~ × 100).

2.12. Data Analysis {#sec2.12}
-------------------

Statistical analyses were performed with one-way ANOVA followed by Tukey-Kramer multiple comparison tests using Graph Pad InStat 3 for windows (GraphPad Software, San Diego, CA, USA).

3. Results {#sec3}
==========

3.1. The *Pi* Infusion Protected Astrocytes against H~2~O~2~-Induced Cell Death {#sec3.1}
-------------------------------------------------------------------------------

H~2~O~2~ exposure is used as a model of ischemia reperfusion. The concentration of H~2~O~2~ used in our experiments (175--200 *μ*M) resembles the concentration reported in rat striatum under ischemic conditions \[[@B3]\]. In order to characterize the ability of the *Pi* infusion to protect against H~2~O~2~-induced oxidative stress, we assessed changes in cell viability and intracellular ROS production, using a model in which oxidative stress was induced by the addition of H~2~O~2~ to cultures of primary astrocytes. Exposure of normal primary astrocytes to H~2~O~2~ resulted in the time and concentration-dependent death of astrocytes at 20 h after exposure (data not shown). To find out whether the *Pi* infusion has a protective effect and to determine the optimal concentration of the extract needed for such an effect, astrocytes were pre-incubated with different concentrations of *Pi* infusion. H~2~O~2~ was then added and was determined after 20 h. Our results show that the *Pi* infusion exhibited a protective effect against H~2~O~2~-induced cell death in a dose-dependent manner ([Figure 1](#fig1){ref-type="fig"}).

The kinetics of H~2~O~2~ cytotoxicity and inhibition in the presence of the *Pi* infusion are presented in [Figure 2](#fig2){ref-type="fig"}. As shown in that figure, H~2~O~2~-induced cytotoxicity reached its maximal level 6 h after the application of H~2~O~2~. The *Pi* infusion prevented the increased incidence of cell death for at least 18 h---the latest time point examined.

To determine the optimal timing of the application of the *Pi* infusion to ameliorate the effect of H~2~O~2~, the cells were pre-incubated with *Pi* infusion for 2 h or 1 h, cotreated or posttreated with H~2~O~2~. Our results demonstrate that the *Pi* infusion is more effective when applied to the cells before H~2~O~2~ and that the addition of *Pi* infusion to the cells after the application of H~2~O~2~ did not provide significant protection ([Figure 3](#fig3){ref-type="fig"}).

3.2. The *Pi* Infusion Inhibited the H~2~O~2~- and ZnCl~2~-Induced Generation of ROS {#sec3.2}
------------------------------------------------------------------------------------

H~2~O~2~-induced cell death is accompanied by an increase in ROS levels. In order to determine whether our *Pi* infusion could inhibit the production of ROS that is induced by H~2~O~2~, we assessed the intracellular generation of ROS and tested whether treatment of astrocytes with the *Pi* infusion affected intracellular ROS levels. For the study of the preventive effects against intracellular ROS formation, the cells were preloaded with the ROS indicator DCF-DA and were treated with various concentrations of *Pi* infusionbefore the application of H~2~O~2~. ROS formation was determined by examining fluorescence every hour for 4 h. As shown in [Figure 4(a)](#fig4){ref-type="fig"}, H~2~O~2~ induced the production of ROS in astrocytes, with the maximum levels of ROS produced after 1 h. Pretreatment of astrocytes with the *Pi* infusion inhibited the H~2~O~2~-induced elevation of the levels of intracellular ROS in a dose-dependent manner ([Figure 4(b)](#fig4){ref-type="fig"}). We also found that treatment with ZnCl~2~ increased ROS generation in astrocytes and that, similar to the effect of the *Pi* infusion H~2~O~2~-induced generation of ROS, this infusion greatly attenuated ZnCl~2~-induced ROS generation ([Figure 5](#fig5){ref-type="fig"}).

To determine the time at which the *Pi* infusion best ameliorates H~2~O~2~-induced ROS production, the cells were pre-incubated with *Pi* infusion for 2 h or 1 h, cotreated or posttreated (for 2 h or 1 h) with H~2~O~2~. Interestingly, in contrast to the results obtained in our cell protection assay ([Figure 3](#fig3){ref-type="fig"}), the *Pi* infusion was similarly effective in attenuating ROS production when it was pre-incubated with the cells and when it was applied after the H~2~O~2~ ([Figure 6](#fig6){ref-type="fig"}). This may indicate that *Pi* treatment sets the cells into a defensive state that helps them to contend with oxidative stress and that it takes about 1 h to get the cells into that defensive state. If this is the case, it indicates that the *Pi* infusion not only is an antioxidant cocktail, but also contains compounds that might bind to a cell surface or intracellular receptor(s) to conduct a protective signal.

3.3. The *Pi* Infusion Reduced 2,2′-Azobis(amidinopropane)-(ABAP-) Mediated Peroxyl Radicals Levels in Astrocytes {#sec3.3}
-----------------------------------------------------------------------------------------------------------------

In addition to H~2~O~2~, various other species, such as peroxynitrite (ONOO^−^), nitric oxide (NO^•^), and peroxyl radicals, have been found to oxidize DCFH to DCF in cell cultures \[[@B51]\]. Therefore, we used a cellular antioxidant activity assay to measure the ability of compounds present in the *Pi* infusion to enter the cells and prevent the formation of DCF by ABAP-generated peroxyl radicals \[[@B52]\]. The kinetics of DCFH oxidation in astrocytes by peroxyl radicals generated from ABAP is shown in [Figure 7(a)](#fig7){ref-type="fig"}. As shown in that figure, ABAP generates radicals in a time-dependent manner and the treatment of cells with the *Pi* infusion moderated this induction. The increase in ROS-induced fluorescence was inhibited by the *Pi* infusion in a dose-dependent manner, as shown in [Figure 7(b)](#fig7){ref-type="fig"}. This indicates that compounds present in the *Pi* infusion entered the cells and acted as efficient intracellular hydroperoxyl radical scavengers.

3.4. Free-Radical Scavenging Activity of *Pi* Infusion {#sec3.4}
------------------------------------------------------

Since many low molecular weight antioxidants may contribute to cellular antioxidant defense properties, we analyzed radical scavenging activity rather than seeking specific antioxidants. The free-radical scavenging activity of the *Pi* infusion was determined by the 2,2-diphenyl-1-picryhydrazyl (DPPH) radical which is considered to be a model lipophilic radical. In this assay, the *Pi* infusion was found to be a very potent free-radical scavenger with an IC~50~ value of 45 *μ*g/mL and 80% inhibition of DPPH absorbance at 517 nm ([Figure 8](#fig8){ref-type="fig"}).

3.5. The *Pi* Infusion Stimulated GDNF Expression in Astrocytes {#sec3.5}
---------------------------------------------------------------

The contrast between the need for a preincubation of the cells with the infusion ([Figure 3](#fig3){ref-type="fig"}) in order to gain the protective effect and the fact that the timing of the addition of the *Pi* infusion did not appear to affect the ability of the treatment to neutralize ROS levels ([Figure 6](#fig6){ref-type="fig"}) led us to examine whether another factor aside from antioxidant activity might be involved in the beneficial effect of the *Pi* infusion. One possible factor could be GDNF secretion. It has been previously shown that GDNF protects astrocytes from ischemia-induced apoptosis \[[@B34]\]. Thus, we raised the possibility that the protective effect of *Pi* infusion on astrocytes suffering oxidative stress might be at least partially due to the induction of GDNF by the *Pi* infusion. This possibility might be supported by the need for preincubation of the *Pi* infusion with the cells in order to elicit the protective effect against H~2~O~2~-induced cell death. To test this possibility, we used real-time PCR and quantified GDNF mRNA. Primary astrocytes were treated with different concentrations of *Pi* infusion for several incubation periods and levels of *GDNF* transcripts were determined. The results of this work showed that incubation with *Pi*infusion at an optimal concentration of 250 *μ*g/mL leads to a 5-fold increase in *GDNF* mRNA levels following 9 h of incubation and a 10-fold increase in *GDNF* mRNA levels following 24 h of incubation ([Figure 9](#fig9){ref-type="fig"}).

4. Discussion {#sec4}
=============

In the present study, we evaluated the effectiveness of the *Pi* infusion for counteracting oxidative damage in cultured astrocytes treated with hydrogen peroxide, zinc, or ABAP. The main findings of this study are that the examined *Pi* infusion can protect primary cultures of rat brain astrocytes from H~2~O~2~-induced cell death and reduce the levels of intracellular ROS produced following treatment with H~2~O~2~, ZnCl~2~, or ABAP. The beneficial effects of the *Pi* infusion are also demonstrated by the induction of astrocyte GDNF expression. Substances that can protect brain cells from oxidative stress are potential tools for the treatment of brain injuries and neurodegenerative diseases. Specifically, the neurotrophic and protective effects of GDNF on neuronal cells that have been demonstrated in previous studies have made GDNF a promising candidate for gene and cell therapy for various neurodegenerative diseases \[[@B53]--[@B55]\].

H~2~O~2~ has been shown to induce the phosphorylation of ERK1/2, AKT/protein kinase B, and ATF-2 in C6 glioma cells \[[@B56]\]. The components of the *Pi* infusion might exert their protective effects by different mechanisms affecting one or more of these processes. Alternatively, or in addition, compounds present in the *Pi* infusion might act as signal-transduction agents to enhance the resistance of astrocytes to oxidative stress induced by ZnCl~2~ and H~2~O~2~, for example, by inducing the expression of neurotrophic factors such as GDNF or upregulating the expression of antioxidant stress-responsive genes such as glutathione S-transferase (GST).

The protective effect of the *Pi* infusion and the observed reduction in ROS levels might be mediated by its antioxidant activities, as was demonstrated by the DPPH experiment. Strong free-radical scavenging activity of a methanolic extract of *Pi* was also reported before \[[@B45], [@B57]\].

In our model, there are two opportunities for compounds present in the *Pi* infusion to elicit antioxidant effects. They can act at the cell membrane to disrupt peroxyl radical chain reactions at the cell surface or they can be taken up by the cell and react with ROS inside the cell. The efficiency of cellular uptake and/or membrane binding combined with that of the radical-scavenging activity dictate the efficacy of the tested infusion. In order to discriminate between these possibilities, astrocytes were pre-incubated with ABAP, which generates ROS inside cells. According to our results, the *Pi* infusion inhibited intracellular ROS levels, suggesting that, in addition to other possible activities, compounds present in the *Pi* infusion may enter the cells and react with ROS inside those cells.

The most popular traditional remedies are infusions or decoctions prepared from plants and herbs. These herbal teas are frequently used in the treatment of chronic diseases, such as cancer, gastrointestinal diseases, and type 2 diabetes. Scientific documentation is available regarding the functionality of herbal and tea extracts that contain different ingredients and have a wide variety of biological effects. For example, green tea (unfermented *Camellia sinensis*) contains large amounts of catechins and vitamin C, has anticancer effects \[[@B58]\], and protects against age-related neurodegeneration \[[@B59]\]. Oolong tea (semifermented *Camellia sinensis*) is known to be an effective treatment for allergic diseases \[[@B60]\] and the suppression of the accumulation of neutral fat \[[@B61]\]. Animal model studies with rooibos (*Aspalathus linearis*) and honeybush (*Cyclopia intermedia*) extracts indicate that teas prepared from both of these plants possess potent immune-modulating and chemopreventive activity \[[@B62]\]. Several other studies have revealed that some herbal medications and antioxidants show promise for the prevention of neurodegenerative diseases \[[@B63]\].

5. Conclusions {#sec5}
==============

Neurodegenerative diseases are multifactorial and strategies for treating these diseases need to include a variety of interventions directed at multiple targets. On the basis of the current results, we suggest that various compounds present in the *Pi* infusion might have beneficial effects and should be further evaluated for the development of a health-promoting functional beverage for the prevention or treatment of brain injuries and neurodegenerative diseases in which oxidative stress and astrocytic cell death play a role. To the best of our knowledge, the effects of *Pi* in the context of neurodegenerative diseases have not been studied previously and this is the first study to characterize the astroprotective effects of this plant.

This work was supported by the Chief Scientist of the Ministry of Science, Israel and by The Israel Science Foundation (Grant no. 600/08). The authors wish to thank Miriam Rinder (The Volcani center) Tatiana Rabinsky (Ben-Gurion University of the Negev) for excellent technical assistance.
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![*Pi*infusion protects astrocytes from H~2~O~2~-induced cell death in a dose-dependent manner. Astrocytes were treated with different concentrations of a *Pi*infusion. H~2~O~2~ was added 2 h after the addition of the *Pi*infusion and cell death was determined 20 h later. The results are mean ± SEM of four experiments (*n* = 16). \*\**P* \< 0.001.](OXIMED2012-157598.001){#fig1}

![Time course of the protective effect of the *Pi* infusion on astrocytes. Astrocytes were preincubated with the *Pi* infusion (100 *μ*g/mL) for 2 h. H~2~O~2~ was then added and cytotoxicity was measured at the indicated time points. The results are the means ± SEM of four experiments (*n* = 16). \*\**P* \< 0.01, \*\*\**P* \< 0.001, compared to cells treated with H~2~O~2~ only.](OXIMED2012-157598.002){#fig2}

![Preincubation of astrocytes with *Pi* infusion is a prerequisite for the protective effect against H~2~O~2~ cytotoxicity*. Pi* infusion (12.5 *μ*g/mL) was added to astrocytes before (−2 h, −1 h) or after (1 h, 2 h) the addition of H~2~O~2~. Cytotoxicity was measured 20 h later. The results are means ± SEM of one experiment (*n* = 4) out of three independent experiments. \*\**P* \< 0.001  \**P* \< 0.01.](OXIMED2012-157598.003){#fig3}

![*Pi* infusion attenuates H~2~O~2~-induced ROS production in astrocytes. Astrocytes were preloaded with the redox-sensitive DCF-DA for 30 min and washed with PBS. Preloaded astrocytes were then pre-incubated with various concentrations of *Pi* infusion for 2 h. H~2~O~2~ (175 *μ*M) was added to the culture and the fluorescence intensity representing ROS production was measured. (a) The fluorescence levels of cells that had been preincubated with 100 *μ*g/mL *Pi* extract were measured at the indicated time points. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 Compared to cells treated with H~2~O~2~ only. (b) The fluorescence levels of cells that had been pre-incubated with various concentrations of *Pi* extract were measured after 3 h. Each point represents the mean ± SEM of two experiments (*n* = 8). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](OXIMED2012-157598.004){#fig4}

![Zinc induces ROS generation and the *Pi* infusion attenuates ROS production following treatment of astrocytes with zinc. Astrocytes were preloaded with DCF-DA for 30 min and washed with PBS. They were then pre-incubated for 2 h with various concentrations of *Pi* infusion. Then, ZnCl~2~ (50 *μ*M) was added and the resulting fluorescence signal was measured at the indicated time points. The results represent means ± SEM of two experiments (*n* = 8). \**P* \< 0.05, \*\*\**P* \< 0.001 compared to cells treated with zinc alone.](OXIMED2012-157598.005){#fig5}

![*Pi* infusion is similarly effective in attenuating ROS production when applied before or after H~2~O~2~. *Pi* infusion (12.5 *μ*g/mL) was added to astrocytes before (−2 h, −1 h) or after (1 h, 2 h) the addition of H~2~O~2~. ROS levels in DCF-DA preloaded astrocytes were measured 1, 4, and 6 h after the application of H~2~O~2~. The results are mean ± SEM of two experiments (*n* = 6). \*\**P* \< 0.001.](OXIMED2012-157598.006){#fig6}

![Peroxyl radical-induced oxidation of DCFH to DCF in primary astrocytes and the inhibition of oxidation by the *Pi* infusion.(a) Astrocytes were incubated for 1 h with *Pi* infusion. Then, the astrocytes were preloaded with DCF-DA for 30 min and washed. ABAP (0.6 mM) was added to the culture and the fluorescence intensity representing ROS levels was measured. (a) The fluorescence levels of cells that had been preincubation with 100 *μ*g/mL *Pi* extract were measured at the indicated time points. \*\*\**P* \< 0.001 compared to cells treated with ABAP only. (b) The fluorescence levels of cells that had been pre-incubated with various concentrations of *Pi* extract were measured at the indicated time points. The results represent means ± SEM of three experiments (*n* = 12). \**P* \< 0.05,\*\**P* \< 0.01, \*\*\**P* \< 0.001.](OXIMED2012-157598.007){#fig7}

![DPPH radical scavenging activity of the *Pi* infusion. The concentration of the infusion was 10 mg/mL. \*\**P* \< 0.001.](OXIMED2012-157598.008){#fig8}

![Treatment with the *Pi* infusion increases the levels of GDNF transcript in primary astrocytes. Rat primary astrocytes were exposed to 250 Mg/mL of *Pi* infusion for 9 or 24 h. Total RNA was then extracted. GDNF transcripts were measured using quantitative real-time PCR. The results of three technical replicates were normalized to glyceraldehyde-3-phosphate (GAPDH) and are expressed as relative quantities of GDNF transcripts. The results are means ± SD of one out of three experiments. Means-paired, one-tailed *t*-tests were used to evaluate the effects of the infusion on the expression of GDNF and the effect of the duration of the incubation. These tests yielded *P*(*t*) values of 0.029 and 0.105, respectively. Therefore, we can conclude that, in cases in which the effect of the duration is not statistically significant, the effect of the *Pi* infusion is significant at a 95% significance level.](OXIMED2012-157598.009){#fig9}
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